eptive and neuropathic pain models, including a capsaicin-induced pain model. In December 2008, TorreyPines announced that NGX426 demonstrated a statistically significant reduction in spontaneous pain, hyperalgesia (abnormally increased pain state) and allodynia (pain resulting from normally non-painful stimuli to the skin) compared to placebo following intradermal injections of capsaicin in a human experimental model of cutaneous pain, hyperalgesia and allodynia.
In order to pursue the Phase II clinical development of NGX426, TorreyPines intends to explore financing and strategic alternatives, including a possible project financing, equity financing, partnership, asset out-licensing or sale of the company.
About TorreyPines Therapeutics, Inc.
TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity, xerostomia and cognitive disorders. The company is currently developing three product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.torreypinestherapeutics.com.
This press release contains forward-looking statements or predictions. Such forward-looking statements include, but are not limited to, statements regarding the potential for NGX426 as a treatment for clinical pain states, including the potential for NGX426 as a treatment for neuropathic pain and acute migraine, and the ability for TorreyPines to successfully complete a strategic or financing transaction. Such statemen
Page: 1 2 3 4 Related biology technology :1
|SOURCE TorreyPines Therapeutics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved
. Max Muscle Introduces First-Ever Probiotics Protein Bar2
. Pharmasset Reports Fiscal First Quarter 2009 Financial Results3
. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY20084
. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)5
. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study6
. World's First Website for Patients to Share Diagnostic-Quality Medical Images7
. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop8
. BioComp Pharma Launches First Generic Drug for Tindamax(R)9
. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor10
. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting11
. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market